Haematologica · 2007 · 138 citations · 7 references
Life SciencesHematologyImmunologyAutoimmunityClinical ImmunologyImmunotherapyAutoimmune DiseasesAutoimmune Hematologic DiseaseHematologic ToxicityImmune-related Adverse EventsImmunosuppressionImmunotherapy SafetyAutoimmune PancytopeniaB Cell AplasiaDose Regimen SelectionImmune-mediated CytopeniasPartial Response AssessmentPure Red Cell AplasiaRituximab-based TherapySafety Profile Characterization
We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7 patients with idiopathic thrombocytopenic purpura and in 1 patient with autoimmune pancytopenia. A partial response was observed in 1 patient with autoimmune hemolytic anemia. The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients.
7
Nichola Cooper, Roberto Stasi, Susanna Cunningham–Rundles et al. · British Journal of Haematology · 2004 · 337 citations · Full text